Skip to main content

Savara Inc. (SVRA)

Stock NASDAQ

$4.26

-0.95 (-18.23%)

Delayed quote.

Price history

Daily close
SVRA daily closing price, Nov 24, 2025 to Nov 20, 2026 Closed at $5.21 on Nov 24, 2025 and $4.26 on Nov 20, 2026, a change of -18.23%. Range $4.22 to $6.94.
Daily closes, Nov 24, 2025 to Nov 20, 2026 (250 trading days).
Start
$5.21
Latest close
$4.26
Period change
-18.23%
Period low
$4.22
Period high
$6.94

Key metrics

Market cap
$939.86M
Volume
17.08M
Average volume
2.48M
52-week range
$4.00 – $7.01
Beta
0.25
Last dividend
—
EPS (TTM)
-$0.61
P/E ratio
-11.38
Revenue (TTM)
$0
Net income (TTM)
-$152.74M
Total assets
$155.93M
Total debt
$31.57M
Cash and equivalents
$29.81M

Key financials (trailing twelve months).

Company profile

Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
CEO
Matthew Pauls
Employees
70
Headquarters
Yardley, PA, US
IPO date
2017-04-28

Financial statements

Annual, last 3 fiscal years. Most recent period first. Reported in USD.

Income statement
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Revenue$0$0$0
Gross profit-$245.0K-$78.03M-$44.26M
Operating income-$123.55M-$103.20M-$60.01M
EBITDA-$118.75M-$102.27M-$59.13M
Net income-$118.84M-$95.88M-$54.70M
Diluted EPS-$0.53-$0.48-$0.33
Balance sheet
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Cash and equivalents$33.18M$15.13M$26.59M
Total assets$253.44M$212.88M$177.56M
Total liabilities$50.30M$41.43M$37.19M
Total debt$29.91M$26.73M$26.49M
Shareholders’ equity$203.13M$171.45M$140.37M
Cash flow statement
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Operating cash flow-$101.04M-$89.09M-$51.06M
Capital expenditure-$22.0K-$25.0K-$296.0K
Free cash flow-$101.06M-$89.11M-$51.36M

Quarterly, last 6 quarters. Most recent period first. Reported in USD.

Income statement
MetricQ3 2026Sep 30, 2026Q2 2026Jun 30, 2026Q1 2026Mar 31, 2026Q4 2025Dec 31, 2025Q3 2025Sep 30, 2025Q2 2025Jun 30, 2025
Revenue$0$0$0$0$0$0
Gross profit$0$0-$66.0K-$40.0K-$20.59M-$385.0K
Operating income-$43.54M-$40.97M-$38.99M-$33.43M-$30.25M-$31.44M
EBITDA-$42.93M-$40.13M-$37.22M-$32.20M-$29.49M-$30.37M
Net income-$42.99M-$40.23M-$37.28M-$32.24M-$29.56M-$30.40M
Diluted EPS-$0.17-$0.16-$0.15-$0.13-$0.14-$0.14
Balance sheet
MetricQ3 2026Sep 30, 2026Q2 2026Jun 30, 2026Q1 2026Mar 31, 2026Q4 2025Dec 31, 2025Q3 2025Sep 30, 2025Q2 2025Jun 30, 2025
Cash and equivalents$29.81M$41.80M$38.79M$33.18M$16.28M$17.44M
Total assets$155.93M$192.14M$221.65M$253.44M$140.92M$163.76M
Total liabilities$48.08M$48.48M$45.61M$50.30M$46.54M$43.28M
Total debt$31.57M$30.11M$30.11M$29.91M$29.83M$29.74M
Shareholders’ equity$107.85M$143.66M$176.04M$203.13M$94.39M$120.48M
Cash flow statement
MetricQ3 2026Sep 30, 2026Q2 2026Jun 30, 2026Q1 2026Mar 31, 2026Q4 2025Dec 31, 2025Q3 2025Sep 30, 2025Q2 2025Jun 30, 2025
Operating cash flow-$42.46M-$29.75M-$33.05M-$25.06M-$22.53M-$26.26M
Capital expenditure-$353.0K-$222.0K-$54.0K-$2.0K-$2.0K-$15.0K
Free cash flow-$42.82M-$29.97M-$33.10M-$25.06M-$22.53M-$26.28M